ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients

T. Schiff, R. Bodin, I. Lee, K. Okumura, D. C. Wolf, A. Dhand, A. L. Gass, D. Spielvogel, G. Veillette, S. Nishida, D. Glicklich, K. Wolfe, T. Diflo, H. Sogawa

New York Medical College/ Westchester Medical Center, Valhalla, NY

Meeting: 2020 American Transplant Congress

Abstract number: C-199

Keywords: Heart transplant patients, Hepatitis C, Kidney transplantation, Liver transplantation

Session Information

Session Name: Poster Session C: Non-Organ Specific: Viral Hepatitis

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: To determine the effects of transplanting an HCV-positive solid organ to an uninfected patient who is on the transplant waiting list and might otherwise die awaiting a transplant. Outcomes include patient and graft survival, HCV infection and infection related complications.

*Methods: Retrospective cohort of all solid organ transplants at a single institution from HCV-positive donors (either HCV-antibody positive and/or HCV-NAT positive) to HCV-negative recipients between July 2017 and October 2019. All recipients received 12 weeks of post-transplant antiviral treatment if HCV-RNA became detectable

*Results: A total of 28 transplants (N=28) from HCV-positive donors to HCV-negative recipients were performed between July 2017 and October 2019. Mean Age of the recipients was 58.3 years. Sex of recipients consisted of males (N=18) and females (N=10). Transplanted organs comprised of heart (N=6), combined heart/kidney (N=2), kidney (N=14), liver (N=5), and combined liver/kidney (N=1). HCV donor serology consisted of 71.4% HCV-Ab positive/HCV-NAT positive (N=20), 17.8% HCV-Ab positive/HCV-NAT negative (N=5), and 10.7% HCV-Ab negative/HCV-NAT positive (N=3). 95% of the recipients receiving an HCV-Ab positive/HCV-NAT positive organ converted to HCV-NAT positive (N=19). The remaining 1 patient to receive an HCV-Ab positive/HCV-NAT positive organ died prior to becoming NAT positive. Conversion rates for recipients receiving either HCV-Ab positive/HCV-NAT negative or HCV-Ab negative/HCV-NAT positive was 0%. For the recipients in which HCV-RNA became detectable post-transplant (N=19), 12 weeks of antiviral treatment was initiated. Apart from 1 patient who is still in the treatment window, all HCV positive recipients were cured after antiviral treatment. 1 patient had a recurrence of HCV, which was cured after a second course of treatment. Total patient survival was 89.3%. A total of 3 patients (N=3) died, 1 in each of the HCV serology subgroups. All 3 patients were NAT negative at time of death. There were two graft losses (kidneys) from the same donor due to Primary Nonfunction. There were no major adverse events secondary to HCV treatment.

*Conclusions: Transplants from HCV-positive donors to HCV-negative recipients appears to be safe, and antiviral treatment was effective. Although all living recipients of HCV-Ab positive/HCV-NAT positive donors developed HCV viremia, the cure rate was 100% for those who completed the antiviral treatment.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Schiff T, Bodin R, Lee I, Okumura K, Wolf DC, Dhand A, Gass AL, Spielvogel D, Veillette G, Nishida S, Glicklich D, Wolfe K, Diflo T, Sogawa H. Solid Organ Transplantation Using Hepatitis C Virus Positive Donor Organs for Hepatitis C Virus Negative Recipients [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/solid-organ-transplantation-using-hepatitis-c-virus-positive-donor-organs-for-hepatitis-c-virus-negative-recipients/. Accessed May 10, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences